Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L

Simply Wall St.

May 07

Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2633972051"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633972051\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633972051?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-07 11:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633972051","market":"us","top_or_hot":-1,"title":"Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L","media":"Simply Wall St.","content":"<div>\n<p>Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-07 11:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB","symbol_name":"美莎比信托","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","article_id":"2633972051","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633972051","pubTimestamp":1778126267,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US regulatory filing.\nSee our latest analysis for Mesoblast.\nDespite the latest clinical milestone, Mesoblast’s 1 day share price return of a 4.13% decline and 7 day share price return of a 5.86% decline show some cooling momentum. However, the 3 year total shareholder return of 102.23% reflects a strong...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB":"美莎比信托","BK7501":"新冠治疗股","MSB.AU":"MESOBLAST LTD","BK4006":"钢铁","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Rexlemestrocel L 3期招募里程碑后评估Mesoblast(ASX：MSB)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB":1.5,"MSB.AU":1.5},"content_text":"Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US regulatory filing. See our latest analysis for Mesoblast. Despite the latest clinical milestone, Mesoblast’s 1 day share price return of a 4.13% decline and 7 day share price return of a 5.86% decline show some cooling momentum. However, the 3 year total shareholder return of 102.23% reflects a strong longer term payoff for investors who remained invested. If this kind of biotech catalyst interests you, it can be worth scanning for other early growth stories. Take a look at 9 healthcare AI stocks With Mesoblast shares down over the past quarter but still showing strong 3 year gains, and trading below some valuation estimates, the key question is whether today’s price leaves potential upside on the table or already reflects expectations of future growth. AdvertisementMost Popular Narrative: 45.4% Undervalued Mesoblast’s most followed narrative pegs fair value at A$3.83 per share, compared with the last close of A$2.09, which creates a sizeable valuation gap to unpack.  The chronic low back pain Phase III program for rexlemestrocel L targets millions of patients and a setting where opioid use is common, aligning the product with an ongoing healthcare shift toward non opioid therapies. If the program succeeds, it could contribute substantially to diversified revenue and reduce reliance on a single product.  Read the complete narrative. Want to see what kind of revenue ramp and margin shift would need to sit behind that fair value, and how long it might take to show up in earnings and cash flows? The narrative leans on a sharp acceleration in growth and a very different profitability profile from today, all compressed into a tight forecast window. Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the narrative could crack if Ryoncil uptake stalls relative to its cash outlay or if key trials suffer delays or weaker than expected readouts. Find out about the key risks to this Mesoblast narrative. Another View: What The Market Multiple Is Saying While the SWS DCF model suggests Mesoblast is trading 32.4% below an estimated fair value of A$3.09, the market is putting a very different price tag on current sales. At a P/S of 30.1x, the stock trades well above both the Australian Biotechs average of 15.4x and a fair ratio of 4.1x. This points to a lot of expectation already in the price. For you, the question is whether that rich sales multiple is a warning sign or a price you are comfortable paying given the DCF upside. See what the numbers say about this price — find out in our valuation breakdown. ASX:MSB P/S Ratio as at May 2026Next Steps If the mixed signals here leave you unsure, that is the right instinct. In this situation, it helps to move quickly and test the thesis against the data. To see exactly what investors are optimistic about, take a closer look at the 3 key rewards Looking for more investment ideas? Do not stop with a single stock when there are tools ready to help you spot other opportunities that fit what you are looking for.  Target potential mispricings by scanning 9 high quality undervalued stocks that combine appealing valuations with stronger fundamentals. Lock in potential income ideas by checking out 9 dividend fortresses that focus on higher yielding opportunities. Prioritise resilience by reviewing the 6 resilient stocks with low risk scores so you can focus on companies with lower assessed risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}